|1.||van Gelder, Teun: 6 articles (06/2012 - 06/2007)|
|2.||Tett, Susan E: 5 articles (11/2015 - 06/2004)|
|3.||Vinks, Alexander A: 5 articles (05/2012 - 05/2008)|
|4.||Oellerich, Michael: 5 articles (04/2011 - 06/2007)|
|5.||Tomillero, A: 5 articles (12/2010 - 09/2008)|
|6.||Moral, M A: 5 articles (12/2010 - 09/2008)|
|7.||Fukuda, Tsuyoshi: 4 articles (05/2012 - 01/2011)|
|8.||Brunner, Hermine I: 4 articles (05/2012 - 01/2011)|
|9.||Armstrong, Victor W: 4 articles (04/2011 - 03/2008)|
|10.||Joy, Melanie S: 4 articles (11/2010 - 01/2009)|
|1.||Psoriasis (Pustulosis Palmaris et Plantaris)
09/01/1977 - "The position of mycophenolic acid in the therapeutic treatment of psoriasis must await the results of a multicenter cooperative study."
05/01/2000 - "Mycophenolic acid is effective for systemic treatment of psoriasis. "
09/01/1997 - "Oral mycophenolic acid (MPA) therapy has been investigated in the treatment of moderate to severe psoriasis since the early 1970s and has been found to be both safe and effective. "
05/01/2000 - "Lack of efficacy of topical mycophenolic acid in psoriasis vulgaris."
12/01/1979 - "Efficacy of mycophenolic acid for the treatment of psoriasis."
|2.||Systemic Lupus Erythematosus (Libman-Sacks Disease)
04/01/2012 - "Effective plasma concentrations of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in the remission-maintenance phase."
01/01/2011 - "Pharmacokinetic variability of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in remission maintenance phase."
01/01/2011 - "The aim of this study was to identify factors affecting the pharmacokinetics of mycophenolic acid (MPA) and its 7-O-glucuronide (MPAG) in systemic lupus erythematosus (SLE) patients. "
06/01/2001 - "The aim of this study was to evaluate the effects of the immunomodulating drug mycophenolic acid (MPA) on splenocytes in an animal model of systemic lupus erythematosus (SLE), using MRLlpr/lpr mice. "
05/01/2012 - "Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus."
12/01/2015 - "Therapeutic monitoring of the serum mycophenolic acid level to enhance the efficacy of MMF in lupus nephritis is being explored. "
08/01/2010 - "Mycophenolic acid (MPA) is an effective treatment for active lupus nephritis despite its variable efficacy in different ethnic groups. "
12/01/2015 - "Therapeutic Drug Monitoring of Mycophenolic Acid in Lupus Nephritis: A Review of Current Literature."
06/01/2013 - "Plasma mycophenolic acid (MPA) concentrations may predict therapeutic response in active lupus nephritis (LN). "
08/01/2010 - "Lertdumrongluk et al. suggest that mycophenolic acid exposure may predict therapeutic responses in severe lupus nephritis, and their initial results confirm that hypothesis. "
05/01/2015 - "In conclusion mycophenolic acid is a potent inducer of HSC apoptosis and attenuates HSC activation and consecutively fibrogenesis in HCV infection. "
07/01/2008 - "Mycophenolic acid (MPA) is used clinically to prevent graft rejection but may increase the risk of fungal infection. "
03/01/2005 - "The exposure to unbound mycophenolic acid was significantly related to infections and haematological toxicity."
07/01/2000 - "Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo."
03/01/2000 - "This new vector can express the gpt product on infection and works as a positive selective marker for mycophenolic acid (MPA) resistance, a potent immunosuppressive drug used in organ rejection therapy. "
01/01/1994 - "Mycophenolic acid is effective against a wide range of experimental tumors in rodents when given orally, despite rapid metabolism to the inactive glucuronide derivative and rapid clearance from plasma. "
01/01/2009 - "The necrotic signal induced by mycophenolic acid overcomes apoptosis-resistance in tumor cells."
05/04/2006 - "Mycophenolic acid (MPA), an immunosuppressive drug, was found to potently inhibit endothelial cell proliferation in vitro and block tumor-induced angiogenesis in vivo. "
01/01/1994 - "The persistence of mycophenolic acid in proliferating cells may account for the effectiveness of once daily dosing against rapidly growing experimental tumors. "
02/01/1981 - "A newly synthesized mycophenolic acid (MPA) derivative, ethyl O-[N-(p-carboxyphenyl)-carbamoyl]-mycophenolate (CAM, NSC-297879D) was tested for antitumor activity, when given orally, against transplantable murine tumors. "
|1.||mycophenolate mofetil (Cellcept)
|4.||Immunosuppressive Agents (Immunosuppressants)
|5.||Adenosine Triphosphate (ATP)
|10.||5'-Guanylic Acid (GMP)
|1.||Transplantation (Transplant Recipients)
|5.||Homologous Transplantation (Allograft)